Treatment of gonorrhea with clavulanate-potentiated amoxicillin (Augmentin)

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Neisseria gonorrhoeae is a significant cause of sexually transmitted infections.
• Antibiotic resistance in N. gonorrhoeae necessitates evaluation of treatment efficacy.
• Amoxicillin trihydrate combined with potassium clavulanate offers a potential therapeutic option.

Purpose of the Study:

• To assess the efficacy of a single oral dose of amoxicillin trihydrate and potassium clavulanate in treating Neisseria gonorrhoeae infections.
• To determine cure rates for infections caused by both penicillinase-producing and non-penicillinase-producing strains of N. gonorrhoeae.
• To evaluate the effectiveness of this regimen in eradicating rectal gonorrhea.

Main Methods:

• A cohort of 161 patients with culture-confirmed Neisseria gonorrhoeae infections was enrolled.
• Treatment involved a single oral dose of amoxicillin trihydrate (3 g) and potassium clavulanate (0.25 g).
• Patients were monitored for treatment outcomes, including cure rates and eradication of rectal infections.

Main Results:

• Overall, 91% of patients infected with non-penicillinase-producing N. gonorrhoeae (139/153) were cured.
• A cure rate of 62.5% (5/8) was observed in patients with penicillinase-producing N. gonorrhoeae strains.
• The treatment achieved a high eradication rate of 97% (30/31) for rectal gonorrhea.

Conclusions:

• A single oral dose of amoxicillin trihydrate and potassium clavulanate demonstrates significant efficacy against Neisseria gonorrhoeae.
• The combination therapy is particularly effective for non-penicillinase-producing strains and rectal infections.
• Further investigation may be warranted for penicillinase-producing strains, though the regimen shows promise.